Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-PV-01 with Pembrolizumab and Chemotherapy in Advanced NSCLC
NCT03380871Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NeoVax in non-small cell lung cancer (NSCLC), sponsored by BioNTech SE. Primary endpoint: Rate of adverse events and severe adverse events leading to treatment discontinuation. Started May 2018; status: completed.
02
Drugs
NeoVax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03380871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380871.